Data compiled by Redley Lamar · ChainSifter Intelligence
10Suppliers
5Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Atossa Therapeutics, Inc. (ATOS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
6Distinct source URLs
10High confidence
0.802Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Atossa Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
PRIMARY-COMMERCIAL-SUPPLIER
PRIMARY-COMMERCIAL-SUPPLIER
92%
In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the (Z)-endoxifen drug substance.
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-31-Z-ENDOXIF
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-31-Z-ENDOXIF
92%
In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the 31 (Z)-endoxifen drug substance.
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-Z-ENDOXIFEN-
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-Z-ENDOXIFEN-
92%
In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the (Z)-endoxifen drug substance.
RODMAN-RENSHAW-LLC
RODMAN-RENSHAW-LLC
92%
Rodman & Renshaw LLC (the “Placement Agent”) acted as the exclusive placement agent for the Company in connection with the Offering.
INTAS-PHARMACEUTICALS-LTD
INTAS-PHARMACEUTICALS-LTD
90%
the Company entered into a Settlement Agreement with Intas Pharmaceuticals Ltd.
JINA-PHARMACEUTICALS-INC
JINA-PHARMACEUTICALS-INC
90%
the Company entered into a Settlement Agreement with Jina Pharmaceuticals, Inc.
THIRD-PARTY-INFORMATION-TECHNOLOGY-VENDOR
THIRD-PARTY-INFORMATION-TECHNOLOGY-VENDOR
90%
We also rely on a third-party information technology vendor to oversee our information technology systems, including our mechanisms, controls, technologies, systems, and other processes designed to h…
Reciprocal relationship from LLY graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from LLY grap…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYN…
Reciprocal relationship from WKEY graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from WKEY graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from WKEY g…
Atossa Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
SNYNF
Sanofi
72%
pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: pandemics, could seriously harm o…
ATHENA-DIAGNOSTICS-INC
ATHENA-DIAGNOSTICS-INC
62%
pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
AUSTRALIA-ATOSSA-GENETICS-AUS-PTY-LTD
AUSTRALIA-ATOSSA-GENETICS-AUS-PTY-LTD
62%
pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
MYRIAD-THERAPEUTICS-INC
MYRIAD-THERAPEUTICS-INC
62%
pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
Atossa Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ATOS-DEBT-7953
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
ATOS-DEBT-7952
Warrants outstanding: 4318475
90%
xbrl warrant detail from xbrl 2026-03-31.
Atossa Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Atossa Therapeutics, Inc..
Atossa Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ATOS-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 3 tracked holders.
Atossa Therapeutics, Inc. Extended Supply Chain Network
